====Dendreon: Targeting Cancer, Transforming Lives
--Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting, Webcast Conference Call,
--April 28, 2009
http://files.shareholder.com/downloads/DNDN/617742340x0x290327/0d56dd47-8426-46dd-ab31-705983b009ca/DNDN_42809_IMPACT_Webcast_Slides_FINAL.pdf
===PROVENGE===
Sipuleucel-T is an autologous active cellular immunotherapy that activates the immune system against prostate cancer
(wli: it is similar to the CVav of PRR functionally)
===Randomized Phase 3 IMPACT Trial===
(IMmunotherapy Prostate AdenoCarcinoma Treatment)
===Four stages for Phase III trials===
--Stage 1
Asymptomatic or Minimally
Symptomatic
Metastatic
Androgen Independent
Prostate Cancer
(N=512)(wli: 512 patients)
**Part one of stage 2
Sipuleucel-T
Q 2 weeks x 3
**Part Two of stage 2
Placebo
Q 2 weeks x 3
--Stage three
PROGRESSION
**Part One of Stage three
Treated at Physician Discretion
**Part two of Stage Four
Treated at Physician discretion and/or Salvage Protocol
--Stage four
SURVIVAL
===========================================
====Primary endpoint:====
Overall Survival
====Secondary endpoint:===
Time to Objective Disease Progression
- Forums
- ASX - By Stock
- IMM
- dendreon
dendreon, page-12
-
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M |
Open | High | Low | Value | Volume |
30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 188729 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 46153 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 76315 | 0.300 |
11 | 188158 | 0.295 |
13 | 374153 | 0.290 |
7 | 1039385 | 0.285 |
9 | 253967 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 4426 | 1 |
0.315 | 57600 | 2 |
0.320 | 165083 | 4 |
0.325 | 239547 | 4 |
0.330 | 68045 | 5 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online